To summarise, there appears to be a progressive and appropriate adaptive immune response measurable in both COVID‐19 and MIS‐C, described by falling naive T cells, activated and proliferating CD4+ T cells, and correlation with the development of neutralising antibodies. The gene discussed is CD4; the disease is COVID-19.